Switching from intravenous to oral alfacalcidol resulted in greater PTH suppression in patients with secondary hyperparathyroidism.
The inverse association is opposite of what is observed in the general population.
Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.
It also is associated with an increased likelihood of hospitalization.
Patients found to have a 67% increased risk of coronary events or death compared with patients who did not suffer acute kidney injury.
The Canadian Society of Nephrology recommends initiation when clinical indications emerge or when the eGFR 6 mL/min/1.73 m2 or below.
A majority of patients on HD have hypertension, and CVD is the leading cause of death in these patients.
USRDS data show a decrease from 116,946 cases in 2010 to 115,643 cases in 2011.
This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.
The adjusted rate fell 26.5% from 1996 to 2011, but remains much higher than in the general population.
New meta-analysis shows no significant increase in hemoglobin or decrease in required erythropoietin dose.
Sexual inactivity is common but not bothersome to many women, study shows.
Levels of bisphenol A in components of dialysis machines may be toxic to immune cells circulating in hemodialysis patients.
An overview of how data from the Centers for Medicare & Medicaid Services' CROWNWeb system could provide additional support.
Novel assay can distinguish between oxidized and nonoxidized forms of parathyroid hormone.
Agency releases a video, a poster, and a pocket guide to help providers and patients prevent development of infectious complications in patients undergoing hemodialysis.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Atorvastatin did not reduce the risk of a combined endpoint of cardiovascular death, MI, and stroke.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Researchers speculate patients on peritoneal dialysis are more physically active than those on HD, and this may lower diabetes risk.
These include use of lower ESA doses and hemoglobin levels.
Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.
Results show an increased risk of mortality and hospitalizations compared with late starts.
Study of patients new to dialysis also demonstrates an increase in the likelihood of hospitalization.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Changes in body weight in advance of dialysis initiation are associated with significantly increased one-year mortality among nursing home residents.
Each 10 cc increment in epicardial adipose tissue is associated with a significant 6% increased risk of death in patients newly started on hemodialysis.
Vascular access-related bloodstream infections were 13 times more likely to develop in patients with than without central venous catheters.